In the following video, Motley Fool health-care analyst David Williamson takes a look back at Vertex's (NASDAQ:VRTX) earnings report this quarter. While it was far from a good quarter for the company, things were somewhat better than expected, leading to a sell-off that wasn't nearly as bad as analysts had feared. David tells us why the company struggled this quarter, and what investors can expect from them in the months to come.

David Williamson has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences, Johnson & Johnson, and Vertex Pharmaceuticals. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.